Clinical Trial

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2026-04-05
Trial Details
NCT Number NCT07190833
Lead Sponsor Bionoxx Inc.
Conditions Treatment-Refractory Solid Tumors
Enrollment 27 participants
Start Date 2026-03-09
Primary Completion 2028-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-09